HSV-thymidine kinase adenoviral gene therapy (Baylor College of Medicine)

N/A

Report date: 2023/10/26 17:10:46

Base Information

Drug NameHSV-thymidine kinase adenoviral gene therapy (Baylor College of Medicine)
Drug Alias NameGene therapy (HSV-tk/GCV)Ad5/F35HSV-tk
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionThymidine phosphorylase stimulants
TargetsThymidine phosphorylase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaylor College Of Medicine
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A